Showing results (631-640 of 834) with videos related to

Sort By:
Pageof 84
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2014
Will post-transplantation cell therapies for pediatric patients become standard of care?Arjan C Lankester, Franco Locatelli, Peter Bader, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2022
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphomaPengcheng He, Haibo Liu, Bryan Zimdahl, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 18, 2002
Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca(2+) activationKathy Pieples, Grace Arteaga, R John Solaro, et al.
Journal for Immunotherapy of Cancer|May 19, 2021
Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cellsZhiliang Bai, Stefan Lundh, Dongjoo Kim, et al.
Blood|September 11, 2007
A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) studyHaydar Frangoul, Eneida R Nemecek, Dean Billheimer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2022
Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy StudiesYimei Li, Wei-Ting Hwang, Shannon L Maude, et al.
Molecular and Cellular Biology|August 15, 2018
CD19 Alterations Emerging after CD19-Directed Immunotherapy Cause Retention of the Misfolded Protein in the Endoplasmic ReticulumAsen Bagashev, Elena Sotillo, Chih-Hang Anthony Tang, et al.
Blood|June 12, 2008
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemiaDavid T Teachey, Cecilia Sheen, Junior Hall, et al.
Bone Marrow Transplantation|May 12, 2015
Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?M A Pulsipher, B Langholz, D A Wall, et al.
Blood|April 12, 2015
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patientsMichael A Pulsipher, Chris Carlson, Bryan Langholz, et al.
Pageof 84